Kiora Pharmaceuticals, Inc. (KPRX)

Market Cap	11.21M +15.6%
Revenue (ttm)	n/a
Net Income	-11.06M
EPS	-2.66
Shares Out	4.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,450
Open	2.630
Previous Close	2.570
Day's Range	2.530 - 2.710
52-Week Range	1.765 - 3.290
Beta	-0.38
Analysts	Buy
Price Target	12.00 (+374.31%)
Earnings Date	Aug 7, 2026

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: KPRX
• Website: https://www.kiorapharma.com

Analyst Summary

According to one analyst, the rating for KPRX stock is "Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(374.31% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 19, 2026

Data Sources Report a data error